Literature DB >> 23681593

Exercise capacity affects quality of life in patients with pulmonary hypertension.

Michael Halank1, Franziska Einsle, Stephanie Lehman, Hinrich Bremer, Ralf Ewert, Heinrike Wilkens, F Joachim Meyer, Ekkehard Grünig, Hans-Jürgen Seyfarth, Martin Kolditz, Gesine Wieder, Gert Höffken, Volker Köllner.   

Abstract

BACKGROUND: The objective of this prospective study was to evaluate the impact of exercise capacity, mental disorders, and hemodynamics on quality-of-life (QoL) parameters in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
METHODS: Sixty-three patients with invasively diagnosed PAH (n = 48) or CTEPH (n = 15) underwent a broad panel of assessments, including cardiopulmonary exercise testing (CPET), 6-minute walking distance (6-MWD), World Health Organization functional class (WHO-FC), and assessment of hemodynamics. QoL was evaluated by the 36-item Medical Outcome Study Short Form Health Survey Questionnaire (SF-36). Exercise capacity, hemodynamics, age, gender, and mental disorders (anxiety and depression) were assessed for association with QoL subscores by uni- and multivariate regression analyses.
RESULTS: Exercise capacity, WHO-FC, oxygen therapy, symptoms of right heart failure, right atrial pressure, and mental disorders were significantly associated with QoL (p < 0.05). In the stepwise backward selection multivariate analysis, depression remained an independent parameter in seven of eight subscales of the SF-36. Furthermore, peak oxygen uptake (peakVO2) during CPET, 6-MWD, anxiety, long-term oxygen therapy, right heart failure, and age remained independent factors for QoL. Hemodynamic parameters at rest did not independently correlate with any domain of the SF-36 QoL subscores.
CONCLUSIONS: Mental disorders, exercise capacity, long-term oxygen therapy, right heart failure, and age play important role in the quality of life in patients with PAH and CTEPH.

Entities:  

Mesh:

Year:  2013        PMID: 23681593     DOI: 10.1007/s00408-013-9472-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  32 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Safety and efficacy of exercise training in various forms of pulmonary hypertension.

Authors:  Ekkehard Grünig; Mona Lichtblau; Nicola Ehlken; Hossein A Ghofrani; Frank Reichenberger; Gerd Staehler; Michael Halank; Christine Fischer; Hans-Jürgen Seyfarth; Hans Klose; Andreas Meyer; Stephan Sorichter; Heinrike Wilkens; Stephan Rosenkranz; Christian Opitz; Hanno Leuchte; Gabriele Karger; Rudolf Speich; Christian Nagel
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

3.  Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Nabil Saouti; Frances de Man; Nico Westerhof; Anco Boonstra; Jos Twisk; Pieter E Postmus; Anton Vonk Noordegraaf
Journal:  Respir Med       Date:  2009-02-20       Impact factor: 3.415

4.  Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population.

Authors:  Louise Ganderton; Sue Jenkins; Stephen P McKenna; Kevin Gain; Robin Fowler; James Twiss; Eli Gabbay
Journal:  Respirology       Date:  2011-11       Impact factor: 6.424

Review 5.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

6.  Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension.

Authors:  Ekkehard Grünig; Nicola Ehlken; Ardeschir Ghofrani; Gerd Staehler; F Joachim Meyer; Jana Juenger; Christian F Opitz; Hans Klose; Heinrike Wilkens; Stephan Rosenkranz; Horst Olschewski; Michael Halank
Journal:  Respiration       Date:  2011-02-09       Impact factor: 3.580

7.  Comparison and validation of three measures of quality of life in patients with pulmonary hypertension.

Authors:  R Chua; A M Keogh; K Byth; A O'Loughlin
Journal:  Intern Med J       Date:  2006-11       Impact factor: 2.048

8.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

9.  Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

Authors:  Roland Wensel; Christian F Opitz; Stefan D Anker; Jörg Winkler; Gert Höffken; Franz X Kleber; Rakesh Sharma; Manfred Hummel; Roland Hetzer; Ralf Ewert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

10.  Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.

Authors:  Joanna Pepke-Zaba; Anthony Beardsworth; Melanie Chan; Mallik Angalakuditi
Journal:  Curr Med Res Opin       Date:  2009-10       Impact factor: 2.580

View more
  21 in total

1.  Economic evaluation of exercise training in patients with pulmonary hypertension.

Authors:  Nicola Ehlken; Cora Verduyn; Henning Tiede; Gerd Staehler; Gabriele Karger; Robert Nechwatal; Christian F Opitz; Hans Klose; Heinrike Wilkens; Stephan Rosenkranz; Michael Halank; Ekkehard Grünig
Journal:  Lung       Date:  2014-03-08       Impact factor: 2.584

2.  [Pulmonary hypertension: Possible genetic causes and therapeutic options].

Authors:  E Grünig; C A Eichstaedt; N Ehlken; E Mayer; H Klose
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

Review 3.  Regulation and interactions in the activation of cell-associated plasminogen.

Authors:  H Myöhänen; A Vaheri
Journal:  Cell Mol Life Sci       Date:  2004-11       Impact factor: 9.261

4.  Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Chakkarin Burudpakdee; Anshul Shah; Vijay N Joish; Christine Divers; Avin Yaldo
Journal:  Am Health Drug Benefits       Date:  2014-12

5.  The effects of pulmonary hypertension on skeletal muscle oxygen pressures in contracting rat spinotrapezius muscle.

Authors:  Kiana M Schulze; Ramona E Weber; Trenton D Colburn; Andrew G Horn; Carl J Ade; Wei-Wen Hsu; David C Poole; Timothy I Musch
Journal:  Exp Physiol       Date:  2021-09-17       Impact factor: 2.858

6.  Variation of PetCO2 during incremental exercise and severity of IPAH and CTEPH.

Authors:  Xingxing Sun; Xue Shi; Yuan Cao; Hanqing Zhu; Bigyan Pudasaini; Wenlan Yang; Ping Yuan; Lan Wang; Qinhua Zhao; Sugang Gong; Jinming Liu; Jian Guo
Journal:  BMC Pulm Med       Date:  2022-06-25       Impact factor: 3.320

Review 7.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

8.  MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.

Authors:  Martin Kolditz; Hans-Jürgen Seyfarth; Heinrike Wilkens; Ralf Ewert; Tom Bollmann; Christiane Dinter; Sabine Hertel; Hans Klose; Christian Opitz; Ekkehard Grünig; Gert Höffken; Michael Halank
Journal:  Lung       Date:  2015-09-12       Impact factor: 2.584

9.  Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH.

Authors:  Elena Pfeuffer; Holger Krannich; Michael Halank; Heinrike Wilkens; Philipp Kolb; Berthold Jany; Matthias Held
Journal:  Lung       Date:  2017-10-09       Impact factor: 2.584

10.  Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Ling-Wei Chen; Ssu-Yuan Chen; Hsao-Hsun Hsu; Yen-Wen Wu; Yu-Mei Lai; Meng-Yueh Chien
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.